Cancer Discovery:大规模临床试验证实:短期禁食是安全的,能增强抗肿瘤免疫力

2022-02-08 nagashi “生物世界”公众号

越来越多的科学研究表明,除了能减肥,禁食对健康的益处甚至更多,它可以改善代谢健康,促进糖尿病、癌症等疾病的治疗。

常言道:人是铁,饭是钢,一顿不吃饿得慌。有趣的是,在世界各地的文化和宗教中,大多都有着禁食相关的风俗习惯,例如斋戒、寒食节等,但这些禁食行为更倾向于锤炼人的精神,或是纪念先人,激励我们追求更高层次的生活。

近年来,禁食成为一种十分流行的减肥方式,在社交网络上,不少人都声称这是最好的减肥方法。值得注意的是,越来越多的科学研究表明,除了能减肥,禁食对健康的益处甚至更多,它可以改善代谢健康,促进糖尿病、癌症等疾病的治疗

2021年11月17日,意大利米兰大学的研究人员在癌症领域顶级学术期刊 Cancer Discovery 上发表了题为:Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in cancer patients 的研究论文。

该研究表明,在接受标准治疗的癌症患者中,涉及短期、严格热量限制的禁食行为是安全、可行的,并导致血糖和生长因子浓度降低,外周血免疫抑制细胞减少,肿瘤内T细胞浸润增强。从而调节癌症患者的新陈代谢,提高抗肿瘤免疫力。

临床前研究已经证明,短期禁食或模拟禁食饮食(FMD)的形式严格限制热量,与标准的药物治疗相结合,具有强大的抗癌效果。然而,热量限制对癌症患者的安全性和生物学效应迄今尚未得到充分的研究。

该研究的第一作者 Claudio Vernieri 博士表示:“我们的首次人体临床试验结果表明,严格的短期热量限制的禁食方案是安全的,且对患者具有生物活性,其活性可能涉及免疫反应的激活。我们认为这些发现可能对癌症治疗十分具有意义。

在这项研究中,研究招募了101名不同类型的肿瘤患者,他们接受不同标准的抗癌治疗。研究团队设计了一项模拟禁食饮食(FMD)方案:在为期五天的禁食周期里,进行低碳水化合物、低蛋白的素食,在第一天摄入热量600千卡,在第2天、第3天、第4天和第5天摄入300千卡,总共在5天内提供了1800千卡。

研究招募了101名不同类型的肿瘤患者

一个模拟禁食周期结束后,患者进入16-23天的恢复期,在此期间,患者没有受到特定的饮食限制,但被建议遵守健康饮食和生活方式的国际指南。每三或四周重复一个禁食周期,最多连续八个周期。

模拟禁食周期流程图

研究人员对所有参与禁食的患者进行统计分析,禁食试验的成功率为91.8%,并满足其主要安全终点。在严格限制热量摄入的5天内,大多数患者在喂食期间体重的下降是可逆的。模拟禁食相关的不良事件发生率为12.9%,其中最常见的是疲劳,但通常并不严重。

这些结果表明,短期严格的热量限制是安全、可行的,并且无论是何种肿瘤类型和抗肿瘤治疗方式,大多数患者耐受良好。

该研究的共同通信作者 Filippo de Braud 博士评论道:“这是一项特别重要的发现,因为它排除了患者可能经历的渐进式体重减轻或营养不良的风险,这些风险与抗癌治疗的疗效降低和生存率降低有关。”

与此同时,研究人员还评估了模拟禁食对患者代谢和免疫反应的影响。在99例可评价的患者中,模拟禁食方案使中位血糖浓度降低了18.6%,血清胰岛素降低了50.7%,血清IGF-1降低了30.3%,这些改变在连续8个周期的过程中保持稳定。

模拟禁食可降低癌症患者的血糖、胰岛素和生长因子IGF-1的水平

Claudio Vernieri 博士表示:“我们在患者中观察到的代谢改变与临床前模型中卡路里限制所引起的代谢改变相似,它们与有效的抗肿瘤作用有关。”

此外,在一项对38名患者为期5天的模拟禁食饮食周期结束后进行的分析中,研究人员发现患者的循环免疫抑制髓细胞亚群显着减少,活化的CD8+T细胞增加。这两种效果均独立于联合抗肿瘤治疗——研究人员也在一小组健康志愿者中观察到类似的现象。

这是因为严格的热量限制产生了一种代谢‘休克’,激活了一些免疫细胞群,这些细胞可以提高标准抗肿瘤治疗的抗肿瘤活性。

模拟禁食减少了癌症患者和健康志愿者中的外周血免疫抑制细胞,并增加了效应T细胞

为了调查模拟禁食饮食对肿瘤内免疫的影响,研究团队对另一项正在进行的试验进行了中期分析,测试了早期乳腺癌和黑色素瘤患者手术前7至10天时进行为期5天的模拟禁食饮食。该分析揭示了肿瘤浸润CD8+T细胞的显着增加和其他变化,表明模拟禁食后抗肿瘤免疫微环境的功能转换。

模拟禁食重塑了乳腺癌患者的肿瘤内免疫力

上述研究结果均表明,模拟禁食饮食有益于癌症患者的代谢健康,增强机体的抗肿瘤能力。并且在全身和肿瘤水平都观察到理想的免疫调节效果。

最后,研究团队表示,最近已经启动了新的临床试验,以了解热量限制所引起的代谢和免疫效应是否具有临床相关的后果,是否能提高抗肿瘤治疗的疗效和延长癌症患者的预期寿命。

关于模拟禁食饮食(FMD)

Valter Longo 教授

这一饮食方式由美国南加州大学的 Valter Longo 教授开发,以5天为一个周期,每个月只需完成一个周期。具体来说:

摄入热量:第1天按每公斤体重11-16卡路里;第2-5天按每公斤体重7-11卡路里。

食物组成:第1天为10%蛋白质+56%脂肪+34%碳水化合物;第2-5天为9%蛋白质+44%脂肪+47%碳水化合物。

当然,这里的食物并非随意选择,以蔬菜、水果、坚果为主,蔬菜做成沙拉或炖菜或汤,它们体积大、热量低,产生饱腹感的同时不至于热量超标。脂肪通过橄榄油提供,蛋白质通过坚果提供,碳水化合物则通过少量的糖和蜂蜜提供。

第6天就可以恢复正常饮食,但要注意过渡,以防消化系统过载,也不要立刻摄入大量糖类和肉类。

 

原始出处:

Claudio Vernieri, Giovanni Fucà, Francesca Ligorio, et al. Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. Cancer Discovery, 2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1783727, encodeId=56251e83727c0, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Nov 11 02:43:52 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043477, encodeId=6e4c20434e70d, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue Jun 21 07:43:52 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013806, encodeId=84a62013806d0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 12 17:43:52 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193874, encodeId=55c711938e443, content=饿死肿瘤细胞, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0b06503639, createdName=ms3000000206173012, createdTime=Wed Feb 16 08:38:45 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307747, encodeId=a61b130e74716, content=<a href='/topic/show?id=85d2289e188' target=_blank style='color:#2F92EE;'>#免疫力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28971, encryptionId=85d2289e188, topicName=免疫力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Thu Feb 10 00:43:52 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587935, encodeId=0fa1158e93589, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Feb 10 00:43:52 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191397, encodeId=1f3b119139e67, content=新的方法诶, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70566386981, createdName=ms8000001368665579, createdTime=Wed Feb 09 12:24:25 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191375, encodeId=485b11913e582, content=不错,值得试试, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d226495138, createdName=ms4000000578805414, createdTime=Wed Feb 09 10:49:15 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191136, encodeId=3cc01191136ed, content=新方法,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 19:39:53 CST 2022, time=2022-02-08, status=1, ipAttribution=)]
    2022-11-11 yahu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1783727, encodeId=56251e83727c0, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Nov 11 02:43:52 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043477, encodeId=6e4c20434e70d, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue Jun 21 07:43:52 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013806, encodeId=84a62013806d0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 12 17:43:52 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193874, encodeId=55c711938e443, content=饿死肿瘤细胞, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0b06503639, createdName=ms3000000206173012, createdTime=Wed Feb 16 08:38:45 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307747, encodeId=a61b130e74716, content=<a href='/topic/show?id=85d2289e188' target=_blank style='color:#2F92EE;'>#免疫力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28971, encryptionId=85d2289e188, topicName=免疫力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Thu Feb 10 00:43:52 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587935, encodeId=0fa1158e93589, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Feb 10 00:43:52 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191397, encodeId=1f3b119139e67, content=新的方法诶, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70566386981, createdName=ms8000001368665579, createdTime=Wed Feb 09 12:24:25 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191375, encodeId=485b11913e582, content=不错,值得试试, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d226495138, createdName=ms4000000578805414, createdTime=Wed Feb 09 10:49:15 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191136, encodeId=3cc01191136ed, content=新方法,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 19:39:53 CST 2022, time=2022-02-08, status=1, ipAttribution=)]
    2022-06-21 ylz8403
  3. [GetPortalCommentsPageByObjectIdResponse(id=1783727, encodeId=56251e83727c0, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Nov 11 02:43:52 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043477, encodeId=6e4c20434e70d, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue Jun 21 07:43:52 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013806, encodeId=84a62013806d0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 12 17:43:52 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193874, encodeId=55c711938e443, content=饿死肿瘤细胞, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0b06503639, createdName=ms3000000206173012, createdTime=Wed Feb 16 08:38:45 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307747, encodeId=a61b130e74716, content=<a href='/topic/show?id=85d2289e188' target=_blank style='color:#2F92EE;'>#免疫力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28971, encryptionId=85d2289e188, topicName=免疫力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Thu Feb 10 00:43:52 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587935, encodeId=0fa1158e93589, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Feb 10 00:43:52 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191397, encodeId=1f3b119139e67, content=新的方法诶, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70566386981, createdName=ms8000001368665579, createdTime=Wed Feb 09 12:24:25 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191375, encodeId=485b11913e582, content=不错,值得试试, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d226495138, createdName=ms4000000578805414, createdTime=Wed Feb 09 10:49:15 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191136, encodeId=3cc01191136ed, content=新方法,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 19:39:53 CST 2022, time=2022-02-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1783727, encodeId=56251e83727c0, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Nov 11 02:43:52 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043477, encodeId=6e4c20434e70d, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue Jun 21 07:43:52 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013806, encodeId=84a62013806d0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 12 17:43:52 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193874, encodeId=55c711938e443, content=饿死肿瘤细胞, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0b06503639, createdName=ms3000000206173012, createdTime=Wed Feb 16 08:38:45 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307747, encodeId=a61b130e74716, content=<a href='/topic/show?id=85d2289e188' target=_blank style='color:#2F92EE;'>#免疫力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28971, encryptionId=85d2289e188, topicName=免疫力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Thu Feb 10 00:43:52 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587935, encodeId=0fa1158e93589, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Feb 10 00:43:52 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191397, encodeId=1f3b119139e67, content=新的方法诶, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70566386981, createdName=ms8000001368665579, createdTime=Wed Feb 09 12:24:25 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191375, encodeId=485b11913e582, content=不错,值得试试, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d226495138, createdName=ms4000000578805414, createdTime=Wed Feb 09 10:49:15 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191136, encodeId=3cc01191136ed, content=新方法,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 19:39:53 CST 2022, time=2022-02-08, status=1, ipAttribution=)]
    2022-02-16 ms3000000206173012

    饿死肿瘤细胞

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1783727, encodeId=56251e83727c0, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Nov 11 02:43:52 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043477, encodeId=6e4c20434e70d, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue Jun 21 07:43:52 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013806, encodeId=84a62013806d0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 12 17:43:52 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193874, encodeId=55c711938e443, content=饿死肿瘤细胞, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0b06503639, createdName=ms3000000206173012, createdTime=Wed Feb 16 08:38:45 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307747, encodeId=a61b130e74716, content=<a href='/topic/show?id=85d2289e188' target=_blank style='color:#2F92EE;'>#免疫力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28971, encryptionId=85d2289e188, topicName=免疫力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Thu Feb 10 00:43:52 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587935, encodeId=0fa1158e93589, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Feb 10 00:43:52 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191397, encodeId=1f3b119139e67, content=新的方法诶, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70566386981, createdName=ms8000001368665579, createdTime=Wed Feb 09 12:24:25 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191375, encodeId=485b11913e582, content=不错,值得试试, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d226495138, createdName=ms4000000578805414, createdTime=Wed Feb 09 10:49:15 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191136, encodeId=3cc01191136ed, content=新方法,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 19:39:53 CST 2022, time=2022-02-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1783727, encodeId=56251e83727c0, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Nov 11 02:43:52 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043477, encodeId=6e4c20434e70d, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue Jun 21 07:43:52 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013806, encodeId=84a62013806d0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 12 17:43:52 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193874, encodeId=55c711938e443, content=饿死肿瘤细胞, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0b06503639, createdName=ms3000000206173012, createdTime=Wed Feb 16 08:38:45 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307747, encodeId=a61b130e74716, content=<a href='/topic/show?id=85d2289e188' target=_blank style='color:#2F92EE;'>#免疫力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28971, encryptionId=85d2289e188, topicName=免疫力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Thu Feb 10 00:43:52 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587935, encodeId=0fa1158e93589, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Feb 10 00:43:52 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191397, encodeId=1f3b119139e67, content=新的方法诶, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70566386981, createdName=ms8000001368665579, createdTime=Wed Feb 09 12:24:25 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191375, encodeId=485b11913e582, content=不错,值得试试, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d226495138, createdName=ms4000000578805414, createdTime=Wed Feb 09 10:49:15 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191136, encodeId=3cc01191136ed, content=新方法,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 19:39:53 CST 2022, time=2022-02-08, status=1, ipAttribution=)]
    2022-02-10 yankaienglish
  7. [GetPortalCommentsPageByObjectIdResponse(id=1783727, encodeId=56251e83727c0, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Nov 11 02:43:52 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043477, encodeId=6e4c20434e70d, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue Jun 21 07:43:52 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013806, encodeId=84a62013806d0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 12 17:43:52 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193874, encodeId=55c711938e443, content=饿死肿瘤细胞, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0b06503639, createdName=ms3000000206173012, createdTime=Wed Feb 16 08:38:45 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307747, encodeId=a61b130e74716, content=<a href='/topic/show?id=85d2289e188' target=_blank style='color:#2F92EE;'>#免疫力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28971, encryptionId=85d2289e188, topicName=免疫力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Thu Feb 10 00:43:52 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587935, encodeId=0fa1158e93589, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Feb 10 00:43:52 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191397, encodeId=1f3b119139e67, content=新的方法诶, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70566386981, createdName=ms8000001368665579, createdTime=Wed Feb 09 12:24:25 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191375, encodeId=485b11913e582, content=不错,值得试试, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d226495138, createdName=ms4000000578805414, createdTime=Wed Feb 09 10:49:15 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191136, encodeId=3cc01191136ed, content=新方法,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 19:39:53 CST 2022, time=2022-02-08, status=1, ipAttribution=)]
    2022-02-09 ms8000001368665579

    新的方法诶

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1783727, encodeId=56251e83727c0, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Nov 11 02:43:52 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043477, encodeId=6e4c20434e70d, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue Jun 21 07:43:52 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013806, encodeId=84a62013806d0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 12 17:43:52 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193874, encodeId=55c711938e443, content=饿死肿瘤细胞, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0b06503639, createdName=ms3000000206173012, createdTime=Wed Feb 16 08:38:45 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307747, encodeId=a61b130e74716, content=<a href='/topic/show?id=85d2289e188' target=_blank style='color:#2F92EE;'>#免疫力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28971, encryptionId=85d2289e188, topicName=免疫力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Thu Feb 10 00:43:52 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587935, encodeId=0fa1158e93589, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Feb 10 00:43:52 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191397, encodeId=1f3b119139e67, content=新的方法诶, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70566386981, createdName=ms8000001368665579, createdTime=Wed Feb 09 12:24:25 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191375, encodeId=485b11913e582, content=不错,值得试试, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d226495138, createdName=ms4000000578805414, createdTime=Wed Feb 09 10:49:15 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191136, encodeId=3cc01191136ed, content=新方法,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 19:39:53 CST 2022, time=2022-02-08, status=1, ipAttribution=)]
    2022-02-09 ms4000000578805414

    不错,值得试试

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1783727, encodeId=56251e83727c0, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Nov 11 02:43:52 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043477, encodeId=6e4c20434e70d, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue Jun 21 07:43:52 CST 2022, time=2022-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013806, encodeId=84a62013806d0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 12 17:43:52 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193874, encodeId=55c711938e443, content=饿死肿瘤细胞, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0b06503639, createdName=ms3000000206173012, createdTime=Wed Feb 16 08:38:45 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307747, encodeId=a61b130e74716, content=<a href='/topic/show?id=85d2289e188' target=_blank style='color:#2F92EE;'>#免疫力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28971, encryptionId=85d2289e188, topicName=免疫力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Thu Feb 10 00:43:52 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587935, encodeId=0fa1158e93589, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Thu Feb 10 00:43:52 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191397, encodeId=1f3b119139e67, content=新的方法诶, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70566386981, createdName=ms8000001368665579, createdTime=Wed Feb 09 12:24:25 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191375, encodeId=485b11913e582, content=不错,值得试试, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d226495138, createdName=ms4000000578805414, createdTime=Wed Feb 09 10:49:15 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191136, encodeId=3cc01191136ed, content=新方法,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Tue Feb 08 19:39:53 CST 2022, time=2022-02-08, status=1, ipAttribution=)]
    2022-02-08 ms3000000637975859

    新方法,值得学习

    0

相关资讯

Nat Biomed Eng:给免疫系统踩油门,MIT开发IL-12+明矾疗法,高效杀伤肿瘤,且副作用更低

癌症,因其难治性和复杂性而被称为“众病之王”。抗击癌症,就像是赛车道上的生死时速——杀死癌细胞的速度要比其增殖速度更快。而在这条生死赛道上,人类一直拥有着一辆顶级的赛车——免疫系统。

知临集团宣布推出针对未解决的突变和新型生物标志物的肿瘤学和自身免疫发现和开发平台

肿瘤学和自身免疫发现和开发平台,最初专注于适应症,包括但不限于非小细胞肺癌(“NSCLC”)和自身免疫性疾病,如狼疮、类风湿性关节炎、炎症性肠病等。

妇科肿瘤患者的生育希望,你需要了解这些

近年来,随着恶性肿瘤发病年龄的年轻化和女性生育年龄的普遍推迟,生育力保护已成为临床制定肿瘤患者治疗方案时,常需权衡和解决的难题。

JAMA Oncology:“烧死”肿瘤!科学家开发远程加热、磁性引导热种子的癌症新疗法

从长远来看,我们将改变热种子的形状,使其充当可以引导穿过组织的微型切割手术刀,这将使外科医生能够执行远程操作,从而彻底改变非侵入性手术。